July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Diabetes
Daily Insulin Dose Tied to Cancer Risk in Patients With T1DM
Daily insulin dose linked to cancer risk in multivariable model, with increasing cancer incidence in low-, medium-, high-dose insulin groups
Noninferiority of Once-Weekly Insulin Icodec Demonstrated in Two T2D Trials
The 26-week ONWARDS 3 and 4 clinical trials evaluated the efficacy and safety of insulin icodec in adults with type 2 diabetes.
Sotagliflozin Under Review for Heart Failure Treatment
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Effect of Keto and Mediterranean Diets on Glucose Control Compared
Limiting added sugar and refined grains helpful, but no added overall health benefit seen for cutting out legumes, fruits, and whole grains
California Will Produce Its Own Insulin to Bring Down Prices
As part of the state’s new budget, $50 million will go directly to the development of low-cost insulin products
Nonmedical Interventions May Improve Type 2 Diabetes Outcomes
Hemoglobin A1C may be lowered by interventions addressing food, education, housing
Abiraterone and Enzalutamide Raise Metabolic, Cardiovascular Adverse Event Risks
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
Insulin Biosimilar Recalled Due to Missing Label on Prefilled Pens
The recalled product does not pertain to the branded interchangeable biosimilar, Semglee (insulin glargine-yfgn).
FDA Extends Review Period for Teplizumab for Type 1 Diabetes Delay
Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
